Irbesartan + Hidroclorotiazida Fisiofen (Hydrochlorothiazide, Irbesartan)

• Irbesartan/Hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin system and promoting diuresis.
• Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension.
• Essential hypertension: helps achieve target blood pressure when monotherapy is insufficient.
• Resistant hypertension: provides additional control when other agents have not achieved desired levels.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion. The combined actions reduce peripheral vascular resistance and plasma volume, resulting in lowered blood pressure.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Increased urination or nocturia
• Fatigue or weakness
• Mild electrolyte disturbances (e.g., low potassium)
• Gastrointestinal discomfort such as nausea

Serious or Rare Side Effects

• Angioedema or severe swelling of face, lips, tongue
• Significant dehydration or electrolyte imbalance
• Hyperkalemia or severe potassium elevation
• Acute renal impairment or rise in serum creatinine
• Severe hypotension, especially after volume depletion
• Allergic reactions including rash or Stevens‑Johnson syndrome

Before initiating therapy, consider the following precautions:

• Renal function monitoring: assess serum creatinine and eGFR regularly.
• Electrolyte balance: watch for hyponatremia, hypokalemia, or hyperkalemia.
• Hepatic impairment: use with caution in severe liver disease.
• Pregnancy: avoid unless benefits outweigh potential risks.
• Concomitant potassium‑sparing agents: increased risk of hyperkalemia.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes or renal impairment.
• Concurrent ACE inhibitors or other ARBs (risk of renal dysfunction and hyperkalemia).
• Potassium supplements or potassium‑sparing diuretics (risk of hyperkalemia).

Moderate Interactions (Monitor Closely)

• NSAIDs (may reduce antihypertensive effect and affect renal function).
• Lithium (possible increase in lithium levels).